Open for feedback
Clozapine: Proposed changes to blood monitoring and prescribing requirements - consultation questions for consumers and families
This Medsafe consultation seeks your feedback on proposed changes to the blood monitoring for clozapine. We are running this consultation on behalf of the companies that distribute clozapine-containing medicines in New Zealand. Clozapine is an antipsychotic medicine used to treat schizophrenia that has not responded to other antipsychotics (treatment-resistant schizophrenia). For safety reasons, there are restrictions around clozapine use in New Zealand and other countries. In some...
Clozapine: Proposed changes to blood monitoring and prescribing requirements - consultation questions for healthcare professionals
This Medsafe consultation seeks your feedback on proposed changes to the blood monitoring and prescribing requirements for clozapine. We are running this consultation on behalf of the companies that distribute clozapine-containing medicines in New Zealand. Clozapine is an antipsychotic medicine used in treatment-resistant schizophrenia. To increase the safety of people taking clozapine, there are restrictions on use of the medicine in New Zealand. In some people, clozapine can...
Proposed amendments to the designated pharmacist prescriber specified prescription medicines list
The Ministry of Health – Manatū Hauora (the Ministry) invites submissions on the proposed addition of 21 prescription medicines and one medicine class (vaccines) to the specified prescription medicines list for designated pharmacist prescribers. The Medicines (Designated Pharmacist—Prescribers) Regulations 2013 permit pharmacist prescribers to prescribe specified prescription medicines. The Ministry, on behalf of the Director-General, must consult with those people or...
Proposed amendments to the designated registered nurse prescriber specified prescription medicines list
The Ministry of Health – Manatū Hauora (the Ministry) invites submissions on the proposed addition of 190 prescription medicines and four medicine classes to the designated registered nurse prescriber specified prescription medicines list. Additionally, feedback is invited on the proposed removal of restrictions for seven medicines currently listed. The Medicines (Designated Prescriber—Registered Nurses) Regulations 2016 and Misuse of Drugs Regulations 1977 permit registered nurse...
Safe Areas - Survey
The Ministry of Health | Manatū Hauora (the Ministry) is conducting its annual survey to understand provider experiences and observations following the establishment of a Safe Area around their facility. The information gathered from this survey will contribute to a review of the effectiveness of Safe Areas surrounding abortion services in Aotearoa New Zealand.
Ngā Paerewa Health and Disability Services Standard Sector Guidance Review
HealthCERT is conducting the second two-yearly review of Ngā Paerewa Health and disability services standard (NZS 8134:2021) Sector Guidance to ensure it remains accurate, relevant, and supportive of sector needs: https://www.health.govt.nz/publications/sector-guidance-for-nga-paerewa-health-and-disability-services-standard-nzs-81342021 This review is an important opportunity to strengthen the guidance so it is practical, clear, and meets the...
Closed for feedback
Topical corticosteroids: Proposal for the package labelling to state their potency
Medsafe is seeking your feedback on a proposed advisory statement for topical corticosteroids to include information about the potency (strength) on the container/package label. In March...
Proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Bioequivalence of medicines
This consultation is aimed at pharmaceutical companies seeking to demonstrate bioequivalence of medicines to support applications to Medsafe for regulatory approval of new and changed products....
Putting Patients First: Modernising health workforce regulation
The Government is inviting New Zealanders to share their views on health workforce regulation by 11.59 pm Wednesday 30 April. On 28 March 2025, the Ministry published a...
Consultation on safety measures for the use of puberty blockers in young people with gender-related health needs
The consultation on safety measures for the use of puberty blockers in young people with gender-related health needs closed on 20 January 2025. We will now consider submissions. Background ...
Unlocking the potential of active ageing - Long-term Insights Briefing publication consultation
The Ministry of Health – Manatū Hauora is seeking written feedback on the proposed topic of its Long-term Insights Briefing by Monday 2 December 2024. Our proposed Long-term Insights Briefing...
Proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Clinical Trials
This consultation is aimed at pharmaceutical companies, health care professional organisations and individuals involved in conducting clinical trials in New Zealand. People who participate in...